EXEL cabozantinib impressive – CHTP raises cash – ALNY NVAX: Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) priced its offering today of 8.75m shares at $4, resulting in net proceeds of $32.8m.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) gave a pipeline update yesterday after hours noting that they continue to enrol patients in their Phase 2b study of ALN-RSV01 and expect to present data from this study in 2012. The Phase 2b study is a double-blind, randomized, placebo-controlled study in Respiratory Syncytial Virus infected lung transplant patients.
Exelixis, Inc. (NASDAQ:EXEL) yesterday reported updated impressive interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing Phase 2 adaptive randomized discontinuation trial. Of 62 patients evaluable by bone scan, 53 (85%) achieved either complete or partial decrease of metastatic lesions on bone scan. Eight other patients (13%) had stable disease (SD) on bone scan, resulting in an overall rate of disease control in bone of 98% (61/62). Only one patient (2%) had progressive disease as their best assessment. EXEL also noted that tumours shrank in 67% of patients with soft-tissue metastatic lesions. Progression Free Survival rates are currently not available as 79% of patients receiving cabozantinib had not showed signs of their disease progressing.
Novavax, Inc. (Nasdaq:NVAX) today presented the final safety and immunogenicity results from their Phase 2 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial. At Day 14, the rates of seroconversion for the 5mcg, 15mcg, and 45mcg dosage groups were 48.3%, 65.0%, and 74.9%, respectively, as compared to 5.9% for the placebo group. Similarly, at day 14, the proportion of subjects who achieved an HAI titer greater than or equal to 1:40 (seroprotection) for the 5mcg, 15mcg, and 45mcg dosage groups increased to 81.6%, 90.5%, and 91.6%, respectively. The second vaccine administration at day 21 did not significantly change the seroconversion and seroprotection rates. Approximately 40% of all subjects had a baseline HAI titer greater than or equal to 1:40 to H1N1 at day 0, either due to exposure to the ongoing pandemic virus, or past exposure. Therefore, a sub-analysis was performed in subjects who were H1N1 seronegative at baseline. In this population, the seroconversion rates for the 5mcg, 15mcg and 45mcg groups were, 64%, 79% and 85%, respectively, after the first dose.